Olmed Solutions 2025: Clinical Proof Has Started, but the Financing Test Is Still Ahead

Company Overview

Olmed looks, at first glance, like a medical-device company with two operating engines. In economic terms, that is no longer the right read. The only live engine is Theroleaf, which is developing RoseDoc, a catheter-based mitral and tricuspid valve replacement system. UniGrd, despite FDA and TGA approvals, is not being manufactured, marketed, or sold. At this stage it is an option on a strategic transaction, not an active business.

What is working now? Theroleaf is no longer just an engineering story. In 2025 the company carried out its first implants in humans: two patients completed the full two-stage process of anchor plus valve implantation, and two additional patients received the anchoring system and are waiting for the second stage. That is a real step up from years of pre-clinical work.

But the active bottleneck is no longer only technological. It is financing and execution at the same time. Olmed ended 2025 with NIS 29.4 million of cash and short-term deposits, no bank debt, but also no sales, no backlog, and NIS 12.1 million of operating cash burn. On top of that sits another yellow flag: the non-binding September 2024 memorandum of understanding for a roughly $2.5 million investment into Theroleaf by a Japanese investor was put on hold during 2025. Clinical proof moved forward, but proof that strategic capital is ready to back that progress still has not arrived.

The easy thing to miss is that even if Theroleaf creates value, not all of that value flows directly to Olmed shareholders. Olmed shows Theroleaf as 100%-owned on a share-capital basis, but only 68.48% on a fully diluted basis. In addition, if Theroleaf or the broader group is sold, part of the net proceeds goes to the sellers of the original mitral-valve assets: 10% of net proceeds, and 15% of the portion above $50 million. That is the core of the story. This is a clinical asset being built, but there are dilution and value-leakage layers between the asset and the listed-company shareholder.

The stock screen is also far from clean. In early April the share traded around 35.9 agorot, implying an equity value of roughly NIS 36 million, with only NIS 2,513 of daily turnover. Short interest is negligible. The immediate practical blocker is not an aggressive bearish positioning story. It is extreme illiquidity.

That mix says something important. Olmed is still built like a narrow development-stage company. Most of its human resources sit in R&D, not in commercial operations, sales, or distribution. That fits the company’s stage, but it also reinforces how little of the story is commercial today.

Events and Triggers

The first trigger: Theroleaf crossed into first-in-human work during 2025. In September the tricuspid anchoring system was implanted in two patients in India under compassionate use, and in December those same two patients completed the second-stage valve implantation. In the same December window, two additional patients received the anchoring system. The India trial is designed for up to 10 patients. This is not commercialization, but it is no longer only animal work either.

The second trigger: In December 2025 Theroleaf received ethics approval for a clinical trial in South Africa and intends to begin implants in the first half of 2026, subject to identifying suitable patients. That matters because it tests whether the company can repeat the procedure beyond the initial India setup.

The third trigger: In December 2025 Theroleaf received approval for an additional Innovation Authority grant of about NIS 1.4 million on a budget of about NIS 4.6 million, with a 30% participation rate. In January 2026 the company received a first payment of NIS 486 thousand. This is useful non-dilutive money, but it needs to be kept in proportion: it supports the trial, it does not replace a broader financing solution.

The fourth trigger: After year-end the company raised $500 thousand through a private placement of 3,921,250 shares to two investors. That is also telling. On one hand, Olmed did bring in more cash. On the other, this is still a small parent-level raise, not something that resets the financing profile of a growing clinical program.

The fifth trigger: UniGrd remains on the table as a transaction option. The company states explicitly that it is seeking a buyer for the assets and IP rights tied to the system. That could turn into value, but until there is an actual deal, there is no reason to treat UniGrd as a funding engine for Theroleaf.

Efficiency, Profitability and Competition

The right way to read 2025 is not through margins, because there is no revenue base here. The question is how the budget moved. The main story is a clear shift away from overhead and into the clinic. R&D expense rose to NIS 8.019 million from NIS 5.902 million in 2024, up about 36%, while G&A fell to NIS 4.998 million from NIS 5.166 million.

That does not mean the company became “efficient” in the classic sense. It means management pushed more money into the only place that can create value at this stage, the clinical program. The board discussion ties the increase mainly to payroll, subcontractors, and raw materials as the human trial started, plus a lower offset from grants. In other words, the higher spend did not come from a bloated corporate layer. It came from moving closer to the patient.

The half-year read reinforces that point. In the second half of 2025, R&D expense rose to NIS 4.305 million from NIS 3.714 million in the first half, while G&A actually edged down slightly.

That matters because it shows where 2026 can go. If site expansion and patient recruitment move forward, R&D should keep rising. If they stall, there is no commercial base to absorb the disappointment.

Another point that is easy to miss is that not all of the worsening bottom line was operational. Operating loss rose to NIS 13.017 million, but total loss reached NIS 14.124 million partly because net finance swung from NIS 2.316 million of income in 2024 to NIS 1.107 million of expense in 2025. The main driver was a NIS 2.497 million FX loss while 55% of the company’s cash and deposits were held in foreign currency and most operating costs were in shekels. Deposit interest still contributed NIS 1.441 million, but it did not offset the currency hit. Part of the pressure, then, reflects balance-sheet positioning rather than only a deterioration in the operating base.

On competition, Olmed is still at a stage where its edge is mainly technological rather than commercial. RoseDoc is targeting a fully percutaneous route with no surgery, and the company argues that competing tricuspid systems remain cumbersome or only narrowly adopted. That may well be true. But at this point it is still a design and positioning claim that needs far more clinical repetition before it becomes a real business moat. UniGrd has a similar issue in reverse: it has regulatory approval and the company highlights technical advantages, but without active sales the competitive question matters mainly for a future transaction, not for current market share.

Cash Flow, Debt and Capital Structure

The balance sheet gives time, but not freedom. Olmed ended 2025 with NIS 4.142 million of cash and NIS 25.245 million of short-term deposits, or NIS 29.387 million of liquid resources in total. Working capital stood at NIS 27.444 million, and there is no bank debt. That is meaningfully more comfortable than what many listed biotech names show at a similar stage.

The right framing here is all-in cash flexibility. In other words, not just how much cash sits on the balance sheet, but how much cash the business actually consumed after real uses of cash. In 2025 the company used NIS 12.082 million in operating cash flow, paid NIS 408 thousand of lease principal, and spent NIS 43 thousand on fixed assets. Together that is roughly NIS 12.5 million of actual annual cash use. On a flat 2025 basis, year-end liquidity covers more than two years of that profile. That is the calming part of the picture.

The less comforting part is that this is backward-looking coverage. If 2026 includes faster patient recruitment, more active sites, and expansion from tricuspid into mitral work, R&D should not stay at 2025 levels. So the year-end cash pile buys time, but it does not necessarily remove the need for another raise.

That chart sharpens another point: the liquidity itself carries currency risk. The company states that 55% of cash and deposits are denominated in foreign currency while most of its operating costs are in shekels. That means the cash cushion can also create earnings volatility, as it did in 2025.

But the deeper issue is not the currency mix. It is the shareholder layer. Buying Olmed does not mean owning 100% of Theroleaf’s upside. The annual report shows Theroleaf as 100%-owned on a share-capital basis, but only 68.48% on a fully diluted basis.

And that comes before the historical mitral-asset seller economics. Under that agreement, if Theroleaf or the group is sold, Olmed must pay the sellers 10% of net proceeds, and 15% of the portion above $50 million. So clinical value created at Theroleaf does not translate one-for-one into value accessible to Olmed shareholders.

This means Olmed is not only a story about cash and trials. It is also a capital-structure story. Anyone reading only the cash balance is missing that.

Outlook

First non-obvious finding: 2026 looks like a clinical proof year, not a breakout year. The company still has no revenue and no backlog, so the next reports will be read mainly through repeatability of the procedure, not through the income statement.

Second non-obvious finding: the financing question remains open. The Japanese-investor MOU was paused, and the new grant covers only 30% of a NIS 4.6 million budget. Helpful, yes. Sufficient, no.

Third non-obvious finding: UniGrd helps only if a transaction actually happens. Until then it is not a funding base, not a revenue engine, and not a reason to cut the company’s risk premium.

Fourth non-obvious finding: even if clinical news stays good, the value that eventually reaches Olmed shareholders may still be lower than a headline read on Theroleaf alone would suggest.

Management lays out three broad directions for the next year: complete the first-in-human tricuspid program and start first-in-human mitral work, advance a strategic transaction around UniGrd, and examine broader product-line expansion. On paper that sounds wide. In practice, investors should read it in reverse order: first prove tricuspid repeatability, then open the mitral track, and only if that advances does it make sense to spend much time on broader portfolio expansion.

That is why the right label for 2026 is a proof year, not a commercialization year and not a breakout year. A company that ends the year with no revenue and no backlog does not suddenly become a commercial story because four patients were treated. The test is whether the trial continues to move, whether patient recruitment and South Africa activation materialize, and whether the company can bring in money without eroding shareholders too aggressively along the way.

There is also a shorter-term market layer here. The next market read is unlikely to focus on the reported loss itself. It is likely to focus on three things: how many additional patients completed the full procedure, whether new sites actually opened, and whether meaningful external capital arrived beyond grants and small private placements. Those are the variables that can change the market’s interpretation of Olmed over the next few quarters.

Risks

The first risk is clinical. Four patients are a start, not a conclusion. As of year-end, only two had completed the full valve-implant step. Any clinical setback, delay, or failure to reproduce the process across more sites would hit the thesis directly.

The second risk is financing. The company has no revenue and no backlog. That means even a NIS 29.4 million liquidity position does not eliminate the need for more capital if clinical activity expands. The suspended strategic investment process in Theroleaf, together with the need for a modest post-balance-sheet private placement, is a reminder that access to funding is still not secured.

The third risk is dilution and value leakage. Olmed shareholders do not own 100% of Theroleaf’s upside on a fully diluted basis, and they do not keep 100% of potential future sale proceeds either. Ignoring that can produce an overly optimistic view of what clinical progress is worth at the listed-company level.

The fourth risk is currency. A large portion of liquidity is held in dollars while most expenses are in shekels. In 2025 that produced a NIS 2.497 million FX loss. This is not a solvency issue, but it is a meaningful source of reported volatility.

The fifth risk is practical. Even if the thesis improves, the stock itself is extremely illiquid. Daily trading in the low thousands of shekels changes how any investor should read the setup. Paper value can improve long before the market can price it smoothly.

Conclusion

Olmed ended 2025 in a better place than where it started the year, but not in a clean one. Theroleaf’s clinical progress is real, the balance sheet still provides time, and there is no bank-debt pressure. On the other side, there is still no commercial engine, strategic financing has not yet been secured, and the path from Theroleaf value to Olmed shareholder value is longer than it looks at first glance.

Current thesis in one line: Olmed moved in 2025 from a pure promise story to a proof story, but not yet to a fully financed or commercialized one.

What changed versus the older read is that the debate around whether the company can execute in humans is now less theoretical. The debate has shifted to a different question: can Olmed turn an initial clinical success into a funded and repeatable path without diluting shareholders faster than it creates value?

The strongest counter-thesis is straightforward: four patients, with only two fully completed procedures, are still too little to justify a value re-rating, and without a partner, deeper financing, or real UniGrd monetization, Olmed may remain a long-running trial story with persistent dilution.

What could change the market read in the short to medium term is a combination of two things together, not one alone: more full procedures that strengthen the clinical profile, and more meaningful outside capital that reduces dilution fear. Without both, even positive partial news may still be read as another step forward inside a long and expensive path.

Why this matters is simple: Olmed is no longer being judged only on the invention. It is now being judged on whether it can move a clinical asset through a double bottleneck of execution and financing.

What has to happen over the next 2-4 quarters for the thesis to strengthen is more completed procedures, active expansion beyond India, and financing or partnership support that gives the clinical plan a longer runway. What would weaken it is repeated delay, more small parent-level raises instead of a broader solution, or another year in which UniGrd remains purely theoretical.